Texas MPN Workshop 2021 | Clinical updates on the use of momelotinib for MPNs
Ruben Mesa, MD, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, talks on the latest results from studies investigating momelotinib for the treatment of myeloproliferative neoplasms (MPNs). Dr Mesa particularly comments on the findings of the MOMENTUM study (NCT04173494) and on momelotinib’s ability to reduce transfusion dependency and to improve symptomatic anemia, an outcome which has been correlated strongly with survival improvement. Although the reasoning behind this clinically meaningful correlation is unclear, it may be due to the alterations in the marrow microenvironment and marrow function that are observed upon anemia improvement. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
